Black Diamond Therapeutics, Inc.

NasdaqGS:BDTX Stock Report

Market Cap: US$167.2m

Black Diamond Therapeutics (BDTX) Stock Overview

A clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. More details

BDTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends0/6

BDTX Community Fair Values

Create Narrative

See what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.

Black Diamond Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Black Diamond Therapeutics
Historical stock prices
Current Share PriceUS$2.95
52 Week HighUS$6.75
52 Week LowUS$1.20
Beta2.72
1 Month Change27.71%
3 Month Change116.91%
1 Year Change-52.50%
3 Year Change-10.33%
5 Year Change-89.85%
Change since IPO-92.53%

Recent News & Updates

Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside

Jun 10

Recent updates

Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside

Jun 10

We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

May 04
We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier

Mar 25

Black Diamond Therapeutics: In Decline, But Why?

Mar 13

Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts

Dec 30

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Oct 30
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data

Oct 08

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Jun 27

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 21
Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Jan 31
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Jan 12

Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

Oct 26
Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 05
Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Jan 16
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Oct 02
Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

Jul 02
Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

Jan 16
We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely

Jun 11
We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely

We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Feb 26
We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Shareholder Returns

BDTXUS BiotechsUS Market
7D18.0%0.4%0.2%
1Y-52.5%-14.8%10.0%

Return vs Industry: BDTX underperformed the US Biotechs industry which returned -11.2% over the past year.

Return vs Market: BDTX underperformed the US Market which returned 11.4% over the past year.

Price Volatility

Is BDTX's price volatile compared to industry and market?
BDTX volatility
BDTX Average Weekly Movement10.5%
Biotechs Industry Average Movement11.4%
Market Average Movement6.4%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.2%

Stable Share Price: BDTX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: BDTX's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201424Mark Vellecawww.blackdiamondtherapeutics.com

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial.

Black Diamond Therapeutics, Inc. Fundamentals Summary

How do Black Diamond Therapeutics's earnings and revenue compare to its market cap?
BDTX fundamental statistics
Market capUS$167.18m
Earnings (TTM)US$5.09m
Revenue (TTM)US$70.00m
32.9x
P/E Ratio
2.4x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BDTX income statement (TTM)
RevenueUS$70.00m
Cost of RevenueUS$0
Gross ProfitUS$70.00m
Other ExpensesUS$64.91m
EarningsUS$5.09m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)0.09
Gross Margin100.00%
Net Profit Margin7.27%
Debt/Equity Ratio0%

How did BDTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/15 13:09
End of Day Share Price 2025/07/15 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Black Diamond Therapeutics, Inc. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhiqiang ShuBerenberg
Arlinda LeeCanaccord Genuity
Robert BurnsH.C. Wainwright & Co.